CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
79.4%−5.2 pts over 5 years
Operating margin
-12.4%−2.0 pts over 5 years
Net margin
-7.0%+9.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.7% | +35.9% | +40.6% | – | |
| Gross profit | +0.5% | +37.5% | +38.8% | – | |
| Free cash flow | -22.5% | – | +40.8% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -4.1% | -5.2% | |
| Return on assets | – | -3.7% | -4.4% | |
| Current ratio | – | 20.58 | 5.26 | |
| Debt to equity | – | 0.00 | 0.02 | |
| Net debt to EBITDA | – | 67.52× | 52.32× | |
| Interest coverage | – | -2.5× | -497.8× | |
| Inventory turnover | – | 5.6× | 7.7× | |
| Capex to revenue | – | 7.6% | 10.5% | |
| Diluted shares | – | 19M | 29M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Castle Biosciences generated $195.48M from operations and spent $87.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$195.48M
Used
$87.08M
Capital expenditure$87.08M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7.0%
×Asset turnover0.62×
×Equity multiplier1.20×
=Return on equity, FY2025-5.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -7.0% | 0.62× | 1.20× | -5.2% |
| FY2024 | 5.5% | 0.67× | 1.16× | 4.3% |
| FY2023 | -26.1% | 0.49× | 1.14× | -14.5% |
| FY2022 | -49.0% | 0.30× | 1.12× | -16.6% |
| FY2021 | -33.3% | 0.21× | 1.09× | -7.6% |
| FY2020 | -16.4% | 0.22× | 1.12× | -4.1% |
| FY2019 | 10.2% | 0.73× | 4.98× | 37.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$24.16M
- Cash generatingOperating cash flow above zero$64.35M
- Return on assets improvedROA up on the prior year4.0% → -4.5%
- Earnings backed by cashOperating cash flow above net income$64.35M vs -$24.16M
- Less leverageLong-term debt to assets fell1.8% → 1.7%
- Better liquidityCurrent ratio rose7.29 → 5.26
- No dilutionShare count did not rise29M → 29M
- Gross margin improvedGross margin up on the prior year81.87% → 79.37%
- More efficientAsset turnover rose0.73 → 0.65